Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest dose and ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...